BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Grove Bank & Trust | 46 | $3,131 | 0.00% |
| CI INVESTMENTS INC. | 3,702 | $252 | 0.00% |
| Venturi Wealth Management, LLC | 161 | $10,960 | 0.00% |
| FIFTH THIRD BANCORP | 3,534 | $240,559 | 0.00% |
| LAZARD ASSET MANAGEMENT LLC | 188 | $12 | 0.00% |
| UMB Bank, n.a. | 48 | $3,267 | 0.00% |
| CARY STREET PARTNERS INVESTMENT ADVISORY LLC | 15 | $1,021 | 0.00% |
| Capital Advisors, Ltd. LLC | 38 | $3 | 0.00% |
| Farther Finance Advisors, LLC | 37 | $2,519 | 0.00% |
| BROWN BROTHERS HARRIMAN & CO | 44 | $2,995 | 0.00% |
| Citadel Advisors | 7,400 | $503,718 | 0.00% |
| True Wealth Design, LLC | 3 | $205 | 0.00% |
| Spire Wealth Management | 155 | $10,558 | 0.00% |
| Avion Wealth | 13 | $0 | 0.00% |
| Versant Capital Management, Inc | 18 | $1,225 | 0.00% |
| Glass Jacobson Investment Advisors llc | 10 | $681 | 0.00% |
| Rise Advisors, LLC | 1 | $64 | 0.00% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 600 | $40,842 | 0.00% |
| WHITTIER TRUST CO | 180 | $12,250 | 0.00% |
| JONES FINANCIAL COMPANIES LLLP | 19 | $1,293 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.